Related Experiment Video
Updated: Aug 14, 2026

Facile Preparation and Photoactivation of Prodrug-Dye Nanoassemblies
Published on: February 17, 2023
Quinone bioreductive prodrugs as delivery agents
Mohammed Jaffar1, Nathalie Abou-Zeid, Li Bai
1School of Pharmacy and Pharmaceutical Sciences, University of Manchester Oxford Road, Manchester M13 9PL, UK. jaff@man.ac.uk
Abstract:
Quinone bioreductive prodrugs were developed to target the hypoxic or the reductase- rich population of solid tumours. The mechanism of their selective activation is based on their ability to convert the quinone sub-structure to their activated semiquinone or hydroquinone species affording the active species. Recent studies on their biochemical activation process have resulted in their development as delivery agents that can effectively release a potent (but not necessarily a cytotoxic) agent under hypoxic/reductive conditions. This technology platform is currently being used to design/identify, and synthesise novel quinone bioreductive delivery agents to target cancer and other diseases where hypoxia and/or reductive enzymes play a major pathophysiological role.
Related Concept Videos
Prodrugs
Prodrugs help overcome...
Drug Biotransformation: Overview
Modified-Release Drug Delivery Systems: Site-Targeted
Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Modified-Release Drug Delivery Systems: Bioavailability
Modified-Release Drug Delivery Systems: Overview

